Tom Powles, Director of Barts Cancer Center, shared a post on X:
“The NADINA trial of neoadjuvant ipi/nivo vs adjuvant nivo in melanoma is a plenary ASCO24 . Shorter periods of therapy in responders (neoadjuvant alone) is an important question. Neoadjuvant nivo didn’t work in RCC (PROSPER). PACIFIC2 struggled in lung.”
Read further.
Source: Tom Powles/X
